Tweet It was demanded that I post as many EAE and Mouse posts as possible from ECTRIMS2025… so happy to oblige. The first post from ECTRIMS2025 is about anti-CD40 ligand this blocks T cells interacting with B cells to deliver their activating signal. However a question I have posed to the students is what does…
Under starters orders and we are off
Tweet It was demanded that I post as many EAE and Mouse posts as possible from ECTRIMS2025… so happy to oblige. The first post from ECTRIMS2025 is about anti-CD40 ligand this blocks T cells interacting with B cells to deliver their activating signal. However a question I have posed to the students is what does…
ECTRIMS2025
Tweet Next up ….Especially for the Requester..Re-inventing a mouse model of EAE…..here we take a mouse that is is essentially empty of mouse T and B cells so we can fill it full of human cells and here they make MOG-reactive CAR-T cells and it makes lesions abit like the Transgenic MOG T cell receptor…
Ocrevus rapidly depletes B-cells, then alters T-cells in MS patients
The CD20 inhibitor Ocrevus (ocrelizumab) rapidly depletes immune B-cells in people with multiple sclerosis (MS), as expected, but ongoing treatment also leads to changes in immune T-cells, a new study […] The post Ocrevus rapidly depletes B-cells, then alters T-cells in MS patients appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
New blood test for MS receives major commercialization funding
Octave Bioscience has raised $35.6 million in funding to continue marketing its multiple sclerosis (MS) disease activity test and accelerate the development of a similar tool for Parkinson’s disease. The […] The post New blood test for MS receives major commercialization funding appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Safety of Rituximab versus Ocrelizumab
Tweet A recent US multi-center study involving over 1,400 patients with multiple sclerosis (MS) has found that those treated with rituximab experienced significantly higher rates of hospitalizations, infections, and hypogammaglobulinemia compared to patients on ocrelizumab. The study analyzed data from UCSF and a larger University of California–wide cohort over a four-year follow-up period. At UCSF,…
New partnership bringing MS biosimilar drug to MENA region
Three biosimilar drugs — approved versions of brand-name therapies that have no clinically meaningful differences compared with their reference products — including one for multiple sclerosis (MS), will soon be […] The post New partnership bringing MS biosimilar drug to MENA region appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
HSCT in the UK
Tweet This paper looks at the outcome of HSCT in the United Kingdom and I guess one question is what DMT can compare? NEDA is no relapse no progression and no MRI so how does the good news on no relapse, no progression and no MRI equate to about 55% having disease? Real-world effectiveness of…
The more MS takes, the more I speak up
Multiple Sclerosis has taken a lot from me over the past 25 years. Building connections and relationships with elected officials, like with our State Senator Roger Hauck, is one way ennifer and I are using our voices following our MS diagnoses. I mean, I could’ve let that be the end of the story when it…
ECTRIMS 2025 Think Hand.
Tweet If you can cast your mind back to ECTRIMS 2016 in London…We were sat outside the Excel Centre in London making our poster for the next days poster session we had some helium balloons saying 95 percent, which was the number of people that were losing hand function with MS and it was part…